The World Health Organization (WHO) announced the availability of a new vaccine on Thursday, clarifying that its initial use will be restricted to high-risk populations and research purposes. Current data indicates that the Ervebo vaccine has demonstrated safety and effectiveness solely against the Zaire strain of the Ebola virus. Critically, the WHO noted that the vaccine has not been proven effective against the Bundibugyo variant, which is currently circulating in the Democratic Republic of Congo.
The distribution of the vaccine is being managed by the WHO’s International Coordination Group for the Supply of Vaccines. This initial allocation includes 20,000 doses designated for the third phase of the Ervebo effectiveness study targeting the Bundibugyo strain. Additionally, 50,000 doses are earmarked for deployment to medical personnel actively managing the epidemic on the front lines.
The ongoing Ebola outbreak in Congo was officially declared on May 15. However, health authorities suggest that the virus may have been circulating in the region for several weeks prior to this official declaration. The epidemic has impacted multiple provinces located in the northern regions of the country, necessitating ongoing international health monitoring and vaccine deployment efforts.
The WHO continues to monitor the evolving nature of the outbreak and the vaccine’s applicability against emerging variants.
Topics: #vaccine #ebola #who
